Iovate Health Sciences International
Iovate Health Sciences International Appoints Raza Bashir Chief Executive Officer
Iovate Health Sciences International announced a leadership change on June 16, 2026. Iovate Health Sciences International named Chief Innovation Officer Raza Bashir Chief Executive Officer, effective immediately, and said it will place an accelerated focus on its core brands and on innovation platforms in peptides, creatine, muscle health, performance, and weight loss.
What changed
Raza Bashir was named Chief Executive Officer.
- Leader: Raza Bashir
- Role: Chief Executive Officer
- Effective: Effective immediately
- Announcement date: June 16, 2026
Leadership background
Bashir most recently served as Chief Innovation Officer at Iovate and has been with the company for nearly two decades. He helped turn science into consumer products for MuscleTech, Hydroxycut, Six Star Pro Nutrition, and Purely Inspired, and led the Iovate/MuscleTech Metabolism and Sport Science Lab partnership with the University of Toronto. He sits on the board of the American Herbal Products Association and holds an MSc in Human Health and Nutritional Science from the University of Guelph.
The mandate
Iovate said it plans an accelerated focus on core brands and innovation platforms in peptides, creatine, muscle health, performance, and weight loss transformation, while building a more agile, consumer-driven organization with stronger supply chain resilience. Bashir said his focus is on bringing entrepreneurial spirit back to the center of how Iovate operates.
Why this matters for GTM teams
Executive appointments can precede changes in strategy, operating cadence, hiring, partnerships, and technology priorities. The useful signal is not the title alone: teams should watch the new leader’s stated mandate, prior playbook, organizational scope, and the initiatives announced during the first two quarters.
Source and methodology
This leadership profile is based on the company’s announcement. Roles, transition timing, and biographical details are presented as announced; SalesTools Research does not infer undisclosed succession plans.
Primary source: Iovate Health Sciences International leadership announcement.
Related Reports
Asembia Appoints David Skomo Chief Executive Officer
Asembia appointed David Skomo as CEO, succeeding co-founder Lawrence Irene, and said he will focus on strengthening the company’s commercial capabilities, technology platform, and pharmacy services.
Lassila and Tikanoja Appoints Ari-Pekka Määttänen President and CEO
Lassila and Tikanoja appointed Ari-Pekka Määttänen, CEO of Fintoil Oy, as President and CEO from May 1, 2027, succeeding Eero Hautaniemi to lead the circular economy company’s next phase of growth.
Sciensus Appoints James Tugendhat Chief Executive Officer
Sciensus has appointed James Tugendhat OBE, most recently Group CEO of HC-One, as Chief Executive Officer, taking over from interim CEO Gordon Cox.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started